Assay of a circulating sodium pump inhibitor in patients with essential hypertension and normotensive subjects.
The plasma levels of a sodium pump inhibitor (Na+ PI) were measured by a modified method of Hamlyn et al, using dog kidney Na+, K+-ATPase. When the level of Na+ PI was expressed as the % inhibition of the enzyme and compared with that of a control solution, it was found to be 9.0 +/- 0.7% in 43 untreated patients with essential hypertension. This was significantly higher than 5.0 +/- 0.4% for 56 normotensive subjects (p less than 0.01). Male patients with essential hypertension showed the highest mean value of 10.5 +/- 1.1%, disclosing an apparent sex difference in the patient group (p less than 0.01). Only in female patients was there a significant positive correlation between the inhibitor's level and the mean blood pressure (r = 0.649, p less than 0.01). These results provided additional evidence for increased Na+ PI in the plasma of patients with essential hypertension, which might bear an important role in the pathogenesis of the disease.
D000328:Adult; D001798:Blood Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood*; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D011506:Proteins / Q000032:analysis*; D012737:Sex Factors; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors*; D000097795:ATPase Inhibitory Protein
D001798:Blood Proteins; D011506:Proteins; D000254:Sodium-Potassium-Exchanging ATPase; D000097795:ATPase Inhibitory Protein